

RESEARCH ARTICLE

Association of Dietary Intake of Folate, Vitamin B₆ and B₁₂ and MTHFR Genotype with Breast Cancer Risk

Ying Liu, Long-Shu Zhou*, Xiao-Ming Xu, Liang-Qing Deng, Qian-Kun Xiao

Abstract

Aim: We aimed to investigate the associations of dietary intake of folate, vitamin B₆ and B₁₂ and MTHFR genotype with breast cancer in a Chinese population. **Methods:** A matched case-control study was conducted, and 435 patients with newly diagnosed and histologically confirmed breast cancer and 435 controls were collected. The folate intake, vitamin B₆ and vitamin B₁₂ were calculated, and MTHFR C665T, C677T and A1298C were analyzed by PCR-RFLP. **Results:** We found vitamin B₁₂ was likely to reduce the risk of breast cancer, and MTHFR 665TT was associated with increased risk of breast cancer. Folate intake, vitamin B₁₂ intake and variants of MTHFR C677T and MTHFR A1298C demonstrated no association with risk of breast cancer. However, we found patients with low intake of vitamin B₆ and MTHFR 665TT genotype had a higher risk of breast cancer (OR=1.87, 95% CI=1.29-2.77), the association being less pronounced among subjects with a moderate intake of vitamin B₆ and MTHFR 665TT genotype (OR=1.58, 95% CI=1.03-2.49, P=0.03). **Conclusion:** Our study indicated that the MTHFR C665T polymorphism and vitamin B₆ are associated with risk of breast cancer, which indicated roles for nutrients in developing breast cancer.

Keywords: Folate - vitamin - MTHFR - polymorphism - breast cancer

Asian Pac J Cancer Prev, 14 (9), 5189-5192

Introduction

Breast cancer is a major health problem worldwide, and it is the leading type of cancer in Chinese females (IARC, 2008). It is known that breast cancer is caused by a complex combination of genetic and environmental factors (Szakacs et al., 2006), and the genes and environment share the stage for most cancers. Exposure to genotoxic agents during breast development, null parity, exposure to ionizing radiation, age at the first child's birth and a family history are well-established risk factors for breast cancer, but majority of the causes is still obscure. However, the DNA repair deficiencies in breast cancer development has been reported to be associated with breast cancer risk due to deficient in the repair of DNA damage (Roberti et al., 2006).

Previous studies have suggested an association between altered diet levels and tumorigenesis (Ulrich et al., 2005), and thus inherited genetic variation in the gene involved in the diet metabolizing enzymes could influence the development of cancer. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism and its catalysis creates an irreversible reduction in 5,10-methylenetetrahydrofolate (THF), which is irreversible reduction in 5,10-methylenetetrahydrofolate (THF), and converted into 5-methyl-THF during process. Previous epidemiologic study indicated the variant of MTHFR C665T (Ala222Val) was associated with risk of

breast cancer (Semenza et al., 2003; Rossi et al., 2006; Yu et al., 2012; Jiao et al., 2013). Another two common MTHFR gene polymorphisms, C677T and A1298C, were widely discussed with the risk of breast cancer (de Cássia et al., 2012; Wu et al., 2012). Therefore, we aimed to investigate the associations of dietary intake of folate, vitamin B₆ and B₁₂ and MTHFR genotype with breast cancer in Chinese population.

Materials and Methods

Subjects

Eligible cases were a consecutive series of female patients with newly diagnosed and histologically confirmed breast cancer. Cases were recruited between January 2009 and December 2010 at The Second Affiliated Hospital of Guangzhou Medical University. Eligible controls confirmed not to have any cancer were selected from the same hospitals during the same period, and one control matched to each case by age (within 5 years). All the cases in our study were collected from patients for health examination and treatment for gynecological. Of all eligible cases, 476 were collected, and 435 patients agreed to participate into our study, with a participation rate of 91.4%.

Face to face interviews were conducted by trained interviewers using a structured questionnaire, and the questionnaire included demographic characteristics,

Table 1. Characteristics of Breast Cancer and Control Subjects

	Cases	%	Controls	%	t or χ^2	P-value
Age (mean±SD), years	47.5±8.5		47.3±8.6		0.35	0.37
Age at menarche, years	12.6±1.7		12.9±1.8		2.5	0.005
Age at first live birth, years	26.2±6.7		23.6±7.1		5.6	<0.001
Menopausal status						
Premenopausal	198	45.5	183	42.1	1.05	0.31
Postmenopausal	237	54.5	252	57.9		
Breast cancer in first-degree relative						
No	406	93.3	433	99.5	24.4	<0.001
Yes	29	6.7	2	0.5		
Folate intake, ug/day	511.5±94.3		516.5±104.2		0.74	0.23
Vitamin B ₆ , mg/day	0.89±0.26		0.89±0.28		1.09	0.14
Vitamin B ₁₂ , ug/day	7.1±3.5		7.7±4.6		2.17	0.02
MTHFR C665T						
CC	139	31.9	168	38.6	6.36	0.04
CT	216	49.7	209	48.1		
TT	80	17.4	58	13.3		
MTHFR C677T						
CC	250	57.5	255	58.6	0.14	0.93
CT	153	35.2	150	34.5		
TT	32	7.3	30	6.9		
MTHFR A1298C						
AA	206	47.4	214	49.3	0.36	0.84
AC	176	40.5	172	39.5		
CC	53	12.1	49	11.2		

medical history, family history of cancer and reproductive factors as well as a food-frequency questionnaire with 86 food terms.

The folate intake, vitamin B₆ and vitamin B₁₂ were computed by multiplying frequency by standard portion size and relative size for each food item in questionnaire, and then the sum of all folate intake from various foods/food groups was calculated as the total folate intake.

Genotype of polymorphisms

Peripheral blood samples were obtained from each case and control, and stored at -20°C until use. Genomic DNA samples were extracted from the blood using QIAGEN FlexiGene DNA kits according to the manufacture's protocol. Genotyping of MTHFR C665T, C677T and A1298C genetic polymorphism was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). The condition of PCR was as follows: initial denaturation at 94°C for 2 min, followed by 35 cycles at 94°C for 30 s, annealing at 60°C for 65 s, extension at 72°C for 90 s, and final extension at 72°C for 5 minutes. A random sample of 5% of cases and controls was genotyped again by different researchers. The reproducibility was 100%.

Statistical analysis

Odds ratios (ORs) were used to measure the association between MTHFR genotype, dietary intake and breast cancer risk. Conditional logistical regression models were used to obtain the estimated ORs and their 95% confidence intervals (CIs) after adjusting for potential confounding variables, and statistical significance was examined by the Wald chi-square test. Stratified analyses were used to evaluate the potential modifying effect of modifying effect of folate intake, vitamin B₆ and vitamin B₁₂ on breast cancer risk with MTHFR genotypes. Statistical analyses were performed by using Stata version 8 (Stata, College Station, TX). P value less than 0.05 was considered to be significant.

Table 2. Associations of MTHFR C665T and Vitamin B₆ intake with breast cancer risk

Dietary intake	MTHFR C665T	OR(95% CI)	P-value
Vitamin B ₆ Low (<0.6 mg/day)	CC	-	
	CT	1.35(0.97-1.74)	0.15
	TT	1.87(1.29-2.77)	0.01
Moderate(0.6-1.0 mg/day)	CC	-	
	CT	1.26(0.91-1.62)	0.26
	TT	1.58(1.03-2.49)	0.03
High (>1.0 mg/day)	CC	-	
	CT	1.11(0.82-1.47)	0.38
	TT	1.42(0.93-2.36)	0.17

Results

The characteristics of cases and controls at baseline are shown in Table 1. The breast cancer cases tended to be older at first live birth, younger at menarche and more first-degree relatives. For dietary habit, we found vitamin B₁₂ were more likely to reduce the risk of breast cancer. However, we did not found intake of vitamin B₆ was associated with risk of breast cancer. For MTHFR gene, MTHFR 665TT was associated with increased risk of breast cancer, and no significant association was found between variants of MTHFR C677T and MTHFR A1298C and risk of breast cancer.

The associations of MTHFR C665T genotypes and Vitamin B₆ intake with breast cancer risk are presented in Table 2, after stratifying by the levels of Vitamin B₆. In terms of low intake of Vitamin B₆, MTHFR 665TT genotype was associated with higher risk of breast cancer (OR=1.87, 95% CI=1.29-2.77, P=0.01), and the association appeared lower among subjects with moderate intake of Vitamin B₆ and MTHFR 665TT genotype (OR=1.58, 95% CI=1.03-2.49, P=0.03). However, no significant association was found in subjects with high intake of high Vitamin B₆ (P=0.17). Moreover, we did not find interaction between MTHFR C665T and Vitamin B₆ (P=0.24).

Discussion

In our study, we found no association between MTHFR C665T polymorphism and Vitamin B₆ and breast cancer risk. However, we did not find a significant association of intake of folate and Vitamin B₁₂ with risk of breast cancer. Our findings are consistent with previous studies on variants of MTHFR gene, folate, vitamin B₆ and vitamin B₁₂ (Semenza et al., 2003; Chen et al., 2005; Cho et al., 2007; Larsson et al., 2007; Gao et al., 2009; Alshatwi et al., 2010; de Cássia et al., 2012; Lajin et al., 2012).

MTHFR is a critical gene in the one-carbon metabolism pathway. Three non-synonymous missense SNPs, C665T, C667T and A1298C, in the coding region were extensively studied. However, the previous association studies on the MTHFR polymorphism and breast cancer risk showed inconsistent results. Several studies have reported that the MTHFR C677T was associated with increased risk of breast cancer in pre-menopausal women or in those with ovarian cancer (Gershoni-Baruch et al., 2000; Ergul

et al., 2003; Maruti et al., 2009), but some others showed no association between MTHFR C677T and breast cancer risk (Vařner et al., 2010; de Cássia et al., 2012). Previous studies reported that MTHFR A1298C was not associated with breast cancer risk in various populations (Vařner et al., 2010; de Cássia et al., 2012; Qiu et al., 2011), while two studies indicated the MTHFR A1298C polymorphism was associated with risk of breast cancer (Hosseini et al., 2011; Akram et al., 2012). Our study did not find significant association between polymorphisms in MTHFR C667T and A1298C and breast cancer risk. The inconsistent of the results might be induced by different populations, sample size, study design and by chance. For MTHFR C665T, various studies reported that variant of MTHFR C665T was associated with risk of breast cancer (Semenza et al., 2003; Rossi et al., 2006; Yu et al., 2012; Jiao et al., 2013). In our study, we found MTHFR C665T polymorphisms was significantly associated with increased risk of breast cancer, which was in line with previous studies.

Generally, folate is able to prevent the development of tumors before established preneoplastic lesions, but it would improve tumorigenesis once lesions have been established (Kim, 2006; Lin et al., 2008; Xu et al., 2008). Although increased folate intake may be good for population deficient in this nutrient, increased intake in women with already-sufficient levels of folate may provide no further benefit or actually harmful. Previous several studies did not report a significant association with breast cancer risk (Vařner et al., 2010; Islam et al., 2013), which is in line with our results. The results indicated folate intake could not play a protective role in breast cancer for women who already have deficient in nutrition.

Our study found that Vitamin B₆ has a protective effect on breast cancer risk. There is a substantial body of data supporting the biological plausibility. Vitamin B₆ acts as a critical coenzyme in two different steps, one is in the synthesis of 5,10- methylenetetrahydrofolate, which is critical for synthesis, repair and methylation of DNA, and another is catabolism of homocysteine to glutathione, which is involved in the detoxification of many carcinogenic compounds and preventing cells from oxidative DNA damage (Selhub et al., 2002; Matsubara et al., 2003). Experimental study suggested that Vitamin B₆ exerts other anticarcinogenic effects by reducing cell proliferation, nitric oxide production and angiogenesis (Matsubara et al., 2003), and clinical studies provide evidence that Vitamin B₆ play a role in protection of breast cancer (Yang et al., 2013). Our study also indicated Vitamin B₆ has an important role in preventing of breast cancer.

In conclusion, our study indicated that MTHFR C665T polymorphism and Vitamin B₆ are associated with risk of breast cancer, which indicated these nutrients have a role in developing breast cancer. Further large sample study are greatly needed to confirm their association.

References

Alshatwi AA (2010). Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR) single

nucleotide polymorphisms. *Food Chem Toxicol*, **48**, 1881-1885.

Akram M, Malik FA, Kayani MA (2012). Mutational analysis of the MTHFR gene in breast cancer patients of Pakistani population. *Asian Pac J Cancer Prev*, **13**, 1599-1603.

de Cássia Carvalho Barbosa R, da Costa DM, Cordeiro DE, Vieira AP, Rabenhorst SH (2012). Interaction of MTHFR C677T and A1298C, and MTR A2756G gene polymorphisms in breast cancer risk in a population in Northeast Brazil. *Anticancer Res*, **32**, 4805-11.

Chen J, Gammon MD, Chan W, Palomeque C, et al (2005). One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. *Cancer Res*, **65**, 1606-14.

Cho E, Holmes M, Hankinson SE, Willett WC (2007). Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. *Cancer Epidemiol Biomarkers Prev*, **16**, 2787-90.

Ergul E, Sazci A, Utkan Z, Canturk NZ (2003). Polymorphisms in the MTHFR gene are associated with breast cancer. *Tumor Biol*, **24**, 286-290.

Gao CM, Kazuo T, Tang JH, et al (2009). MTHFR polymorphisms, dietary folate intake and risks to breast cancer. *Zhonghua Yu Fang Yi Xue Za Zhi*, **43**, 576-80.

Gershoni-Baruch R, Dagan E, Israeli D, et al (2000). Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. *Eur J Cancer*, **36**, 2313-6.

Hosseini M, Houshmand M, Ebrahimi A (2011). MTHFR polymorphisms and breast cancer risk. *Arch Med Sci*, **7**, 134-7.

Islam T, Ito H, Sueta A, et al (2013). Alcohol and dietary folate intake and the risk of breast cancer: a case-control study in Japan. *Eur J Cancer Prev*, **22**, 358-66.

Jiao Z, Li D (2013). Lack of association between MHTFR Glu429Ala polymorphism and breast cancer susceptibility: a systematic review and meta-analysis of 29 research studies. *Tumour Biol*, **34**, 1225-33.

Kim YI (2006). Does a high folate intake increase the risk of breast cancer? *Nutr Rev*, **64**, 468-75.

Larsson SC, Giovannucci E, Wolk A (2007). Folate and risk of breast cancer: a meta-analysis. *J Natl Cancer Inst*, **99**, 64-76.

Lajin B, Alhaj Sakur A, Ghabreau L, Alachkar A (2012). Association of polymorphisms in one-carbon metabolizing genes with breast cancer risk in Syrian women. *Tumour Biol*, **33**, 1133-9.

Lin J, Lee IM, Cook NR, et al (2008). Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. *Am J Clin Nutr*, **87**, 734-43.

Matsubara K, Komatsu S, Oka T, Kato N (2003). Vitamin B₆-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis. *J Nutr Biochem*, **14**, 246-50.

Maruti SS, Ulrich CM, Jupe ER, White E (2009). MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study. *Breast Cancer Res*, **11**, R91.

International Agency for Research on Cancer (2008). Globocan 2008, China. <http://globocan.iarc.fr/factsheet.asp>, IARC.

Qiu LX, Zhang J, Li WH, et al (2011). Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility. *Mol Biol Rep*, **38**, 2295-9.

Szakacs G, Paterson JK, Booth-Genthe C, Gottesman MM (2006). Targeting multidrug resistance in cancer. *Nat. Rev. Drug Discov*, **5**, 219-34.

Roberti A, La Sala D, Cinti C (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new

- therapeutic prospective. *J. Cell Physiol*, **207**, 571–81.
- Rossi E, Hung J, Beilby JP, Knuiman MW, et al (2006). Folate levels and cancer morbidity and mortality: prospective cohort study from Busselton, Western Australia. *Ann. Epidemiol*, **16**, 206–12.
- Selhub J (2002). Folate, vitamin B₁₂ and vitamin B₆ and one-carbon metabolism. *J Nutr Health Aging*, **6**, 39–42.
- Semenza JC, Delfino RJ, Ziogas A, Anton-Culver H (2003). Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. *Breast Cancer Res. Treat*, **77**, 217–23.
- Ulrich CM (2005). Nutrigenetics in cancer research—folate metabolism and colorectal cancer. *J. Nutr*, **135**, 2698–702.
- Xu X, Gammon MD, Wetmur JG, Bradshaw PT, et al (2008). B-vitamin intake, one-carbon metabolism, and survival in a population-based study of women with breast cancer. *Cancer Epidemiol Biomarkers Prev*, **17**, 2109–16.
- Yang D, Baumgartner RN, Slattery ML, et al (2013). Dietary intake of folate, B-vitamins and methionine and breast cancer risk among Hispanic and non-Hispanic white women. *PLoS One*, **8**, e54495.
- Yu L, Chen J (2012). Association of MTHFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: An update meta-analysis based on 51 research studies. *Diagn Pathol*, **7**, 171.
- Vařner AS, Boiarskikh UA, Voronina EN, Selezneva IA, et al (2010). Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR, C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in West Siberian Region of Russia. *Mol Biol (Mosk)*, **44**, 816–23.
- Wu XY, Ni J, Xu WJ, et al (2012). Interactions between MTHFR C677T-A1298C variants and folic acid deficiency affect breast cancer risk in a Chinese population. *Asian Pac J Cancer Prev*, **13**, 2199–06.